Ongoing viral replication and production of infectious virus in patients with chronic hepatitis B virus suppressed below the limit of quantitation on long-term nucleos(t)ide therapy

• Published in: PloS one Vol. 17; no. 4; p. e0262516
• Main Authors: Burdette, Dara L, Lazerwith, Scott, Yang, Jenny, Chan, Henry L Y, Delaney Iv, William E, Fletcher, Simon P, Cihlar, Tomas, Feierbach, Becket
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01.04.2022; Public Library of Science (PLoS)
• Subjects: Analogs; Animals; Antiviral Agents - pharmacology; Antiviral Agents - therapeutic use; Biology and Life Sciences; Complications; Deoxyribonucleic acid; DNA; DNA viruses; DNA, Viral; Equivalence; Genomes; Hepatitis; Hepatitis B; Hepatitis B virus - genetics; Hepatitis B, Chronic; Humans; Infections; Infectivity; Laboratory animals; Liver cancer; Medicine and health sciences; Mice; Nucleosides - adverse effects; Patients; Quantitation; Replication; Research and Analysis Methods; Therapy; Titration; Viral infections; Virology; Virus Replication; Viruses; United States > US; Japan
• DOI: 10.1371/journal.pone.0262516
• ISSN: 1932-6203

Nucleos(t)ide analogs are standard-of-care for the treatment of chronic hepatitis B and can effectively reduce hepatitis B virus (HBV) replication but rarely leads to cure. Nucleos(t)ide analogs do not directly eliminate the viral episome, therefore treatment cessation typically leads to rapid viral rebound. While treatment is effective, HBV DNA is still detectable (although not quantifiable) in the periphery of the majority of nucleos(t)ide analog treated HBV patients, even after prolonged treatment. Addressing whether the detectable HBV DNA represents infectious virus is a key unknown and has important implications for the development of a curative treatment for HBV. The minimum HBV genome equivalents required to establish infection in human liver chimeric mice was determined by titration of HBV patient sera and the infectivity in chimeric mice of serum from patients (n = 7) suppressed to the limit of detection on nucleos(t)ide analog therapy was evaluated. A minimum of 5 HBV genome equivalents were required to establish infection in the chimeric mice, confirming this model has sufficient sensitivity to determine whether serum from virally suppressed patients contains infectious virus. Strikingly, serum from 75% (n = 3 out of 4) of nucleos(t)ide-treated HBV patients with DNA that was detectable, but below the lower limit of quantitation, also established infection in the chimeric mice. These results demonstrate that infectious virus is still present in some HBV patients on suppressive nucleos(t)ide therapy. This residual virus may support viral persistence via continuous infection and explain the ongoing risk for HBV-related complications despite long-term suppression on therapy. Thus, additional treatment intensification may facilitate HBV cure.